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ABSTRACT 
Background: Maternal mortality ratio (MMR) is a significant healthcare marker used to evaluate 
the quality of health in a population. The wide range of MMR (from 5 to more than 500 deaths 
per 100,000 births) indicates that there is still a robust global effort in reducing maternal death 
in developing countries, especially sub-Saharan Africa, where the MMR burden is the highest. 
Postpartum hemorrhage (PPH), defined as a blood loss of 500 ml or more within 24 hours after 
delivery is the leading cause of maternal death worldwide. In developed countries, the natural 
physiologic action of oxytocin, a uterotonic hormone, has been used in reducing PPH during the 
third stage of labor. Since 2011, misoprostol has been added to the Essential Medicines List by 
the WHO. The WHO guidelines also recommended misoprostol, a prostaglandin E1 analog as a 
favorable alternative in settings where oxytocin is not available.    
Objective: This scholarly project is a systematic review with a focus on the administration of 
misoprostol (200-1000 𝜇𝜇g PO, sublingually or rectally) during the third stage of labor in Sub-
Saharan African women of reproductive age (age 15-44). It is hypothesized that the 
implementation of misoprostol during the third stage of labor is a valuable alternative of 
oxytocin and will reduce the incidence or severity of PPH in Sub-Saharan Africa (with an 
outcome primarily measured in estimated blood loss (EBL) in mL).  
Methods: PubMed and the International Journal of Obstetrics and Gynecology were the main 
databases of this systematic review. The main inclusion criterion in the search was region of 
interest (Sub-Saharan Africa). The initial 35 primary articles were then further evaluated and 
the final seven articles were selected based on their primary outcomes (EBL in mL), region (Sub-
Saharan Africa) and purpose (comparing (1) misoprostol with the gold-standard, oxytocin or 
with a controlled placebo and (2) two different doses of misoprostol). 
  
Results: Three meta-analyses using a Cohen’s D scale were generated from the data collected in 
this study. The overall result of the first meta-analysis favors the use of oxytocin over 
misoprostol [-0.13 (95% CI -0.26, 0.01)]. The two main conclusions drawn from this meta-
analysis are, (1) there is a tendency for oxytocin to have a positive effect on blood loss but (2) 
since the overall result is not statistically significant, misoprostol also have a positive effect on 
blood loss. In the second meta-analysis, the effect of two different doses of misoprostol (400 
and 600 mcg) on blood loss are compared. The results demonstrated that there is an effect 
modification on the overall population and dosage was found to be a confounder in blood loss 
[-0.13 (95% CI -0.26, 0.01)]. Lastly, the third meta-analysis compared the effect that adding 
oxytocin to misoprostol to control postpartum blood loss, has on EBL. Overall, the main 
conclusion drawn from this meta-analysis is that there is no statistical significance in adding 
oxytocin to a misoprostol regimen and in this case, the addition of oxytocin does not have a 
confounding effect on misoprostol [-0.13 (95% CI -0.26, 0.01)].  
Conclusion: Based on the results of this systematic review, it was supported that oxytocin 
should remain the gold-standard drug in settings where it is available. However, it was also 
proven that misoprostol remains a valuable alternative in places where oxytocin is unavailable.  
Keywords: Maternal mortality, post-partum hemorrhage, oxytocin, misoprostol, sub-Saharan 
Africa 
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1 
INTRODUCTION, SIGNIFICANCE, RATIONALE 
Sub-Saharan Africa and the burden of Maternal Mortality  
Maternal mortality is one of the significant healthcare markers used to evaluate the quality of 
care in a population. Based on the World Health Organization, it is estimated that 
approximately 800 women die every day due to preventable causes related to pregnancy and 
childbirth. As of November 2015, 303,000 women worldwide died annually during or following 
childbirth1. 66.3% (201,000) of these deaths occurred in Sub-Saharan Africa alone, carrying the 
heaviest burden of Maternal Mortality Ratio (MMR)1. Globally in 2015, Maternal mortality 
ratios ranged from 5 deaths per 100,000 lives in developed nations (e.g. in Finland, Sweden and 
Greece) to 546 deaths per 100,000 in developing countries (e.g. in Cameroon, Cote d’Ivoire, 
Somalia and Kenya)1. These statistics clearly highlight the global disparity in maternal mortality.  
To this day, significant effort is still required to decrease maternal mortality in many countries.  
Since 2000, reducing maternal health is one of the eight Millennium Development Goals 
(MDG5). Countries worldwide were devoted to reduce their MMR by three quarters over a 25-
year period (from 1990 to 2015)1-2. By the end of 2015, maternal death dropped by 43.9% 
worldwide, with an annual decline of approximately 2.3% (from 1990 – 2015)1. Despite the 
mobilized efforts, MMR was only halved in Sub-Saharan African countries1. A new global 
Sustainable Development Goal (SDG) was recently established, with an ambitious projected 
MMR of less than 70 maternal deaths per 100,000 live births by 20301. To meet this 
requirement, identifying and targeting the main causes of maternal deaths need to be 
reinforced and will inevitably require a much more robust global effort1.  
The main causes of maternal deaths worldwide include postpartum hemorrhages (PPH, 27%), 
hypertensive disorders during pregnancy (pre-eclampsia and eclampsia, 18.5%), postpartum 
infections (11%) and complications during pregnancy and unsafe abortions (approximately 
18%). Such conditions are aggravated with indirect socioeconomic factors such as poverty, 
malnutrition, anemia and the high prevalence of pre-existing infectious diseases (primarily 
malaria, hepatitis and HIV/AIDS).3 
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This systematic review will specifically focus on PPH, the leading cause of maternal death in 
Sub-Saharan Africa.  
Post-Partum hemorrhages and risk factors 
PPH is a medical condition that can occur up to 24 hours after birth. PPH is defined as a vaginal 
blood loss of 500 ml or more during this timeframe. Severe PPH is blood loss of 1000 ml or 
more also within the first 24 hours postpartum. The number one cause of maternal death 
worldwide, PPH can lead to other medical emergencies including shock and organ dysfunction.4 
After a normal childbirth and upon placental delivery, uterine bleeding is controlled by two 
mechanisms, (1) the contraction of the myometrium, which eventually compresses the blood 
supply of the placental bed, causing mechanical hemostasis, (2) initiation of the clotting 
cascade regulated by local decidual hemostasis factors. A pathogenic event that causes a 
disturbance in one of these two mechanisms (e.g. genital tract trauma, bleeding diathesis, 
incomplete placental separation or defective myometrial contraction) results in PPH. Uterine 
atony accounts for at least 80 percent of PPH. Risk factors associated with PPH include multiple 
gestation, prolonged labor, infection, and multiparity, even though most PPH cases occur in 
women with no significant past medical history. Women with additional co-morbidities (such as 
pre-existing anemia) have higher risks of morbidity and mortality after PPH4.   
The Active Management of the Third Stage of labor (AMTSL) and Misoprostol  
Active management of the third stage of labor (AMTSL) has proven to reduce PPH by 66%. The 
three key actions of AMTSL consist of (1) administrating uterotonic drugs to the new mother 
within one minute of childbirth, (2) a controlled placental delivery by cord traction and (3) a 
uterine massage. The use of recommended uterotonic drugs (oxytocin, ergometrine or the 
combination of both) right after delivery is very critical in preventing PPH. Failure of the uterus 
to contract properly after childbirth will cause bleeding from the genital tract of 500 mL or 
more within the first 24 hours postpartum, leading to PPH4.  
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Oxytocin (IM/IV, 10 UI)4, a hormone that induces uterine contractions after birth is the drug of 
choice for the AMTSL4. The use and feasibility of oxytocin in developing countries remains very 
limited because of its storage and administration protocols (i.e. requires a skilled health 
provider, cold chain storage and sterile syringes and needles)6-7.  
These storage and administration challenges with oxytocin have led to increased interest in 
misoprostol, a synthetic prostaglandin E1 analogue, as a practical alternative in developing 
areas where oxytocin is not accessible. One of the most important advantages of Misoprostol 
over oxytocin is the possibility of oral administration, in addition to reasonable cost, and a long 
shelf life at room temperature8. Additionally, administering misoprostol (400 – 600 𝜇𝜇g) 
sublingually allows a faster onset of action and a greater bioavailability by avoiding first-pass 
metabolism6.  
Despite these WHO guidelines and the evidence that misoprostol is a convenient alternative in 
settings where oxytocin is not available, implementing the use of uterotonic drugs is still a 
challenge. Perhaps this could be due to difficulty in facilitating the distribution of misoprostol or 
the proper use of the medication in settings where the targeted population is not trained to do 
so. 
Rationale and Significance 
A number of studies have been done in different Sub-Saharan countries (e.g. Nigeria, Liberia, 
Tanzania and Uganda) to evaluate the benefits and efficacy of Misoprostol in preventing PPH.  
A systematic review that analyses the outcomes of such studies has not yet been performed.  
Based on the statistics discussed above, the robust effort necessary to significantly reduce 
maternal deaths by 2030, in addition to the pharmaceutical and clinical promises of 
misoprostol, this Global Health systematic review proves itself to be extremely relevant to 
women’s health. Positive findings of this study would support the use of misoprostol as a gold-
standard alternative of oxytocin and encourage operationalization of implementation 
programs.  
4 
METHODS 
Since this is a new research, there is no preliminary data collected. However, as further 
discussed in the subsequent sections, there are 35 preliminary selected articles for this review 
(23 are primary articles) [All references to Figure 1].   
Databases 
PubMed is my main research source. Access to the International Journal of Obstetrics and 
Gynecology online was obtained through my mentor.  
Inclusion/Exclusion criteria  
The main inclusion criterion was the medical condition (postpartum hemorrhage), misoprostol 
and the region of interest (sub-Saharan Africa). 
Keyword search strings 
- PubMed Terms: Misoprostol postpartum hemorrhages: 380 results 
o Misoprostol postpartum hemorrhages:  
 Advanced search with: 
 Mesh Terms: Africa, sub Saharan: 35 results  
 23/35 of these articles are usable primary articles for my study.  
 
- Additional keyword search String (PubMed): Cytotec Postpartum hemorrhage:  
416 results  
o Cytotec Postpartum hemorrhage: 
 Advanced search with: 
• Mesh Terms, Africa: 42 results  
o 35 of the results are the same as articles from the original 
search (see above) 
o 8/42 were new results and did not qualify for this study. 
 
  
5 
Analyses and outcomes 
The identified studies from the selected studies all have measurable outcomes. Such outcomes 
include but are not limited to blood loss (in mL), blood hemoglobin concentration after birth, 
feasibility, acceptability, effectiveness of distribution mechanisms and uterotonic coverage. 
However, for the original purpose of this systematic review and the emphasis on PPH, 
estimated blood loss (EBL) in mL is the primary outcome used for results and data analysis. 
Tables, figures and data analysis were all performed by using Excel and Stata version 14 and 
reviewed by Paul Kang, a biostatistician.  
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Figure 1. Key search strings 
 
 
 
PubMed
Primary search: 
Misoprostol postpartum 
hemorrhages
380 results
Advanced search with
Mesh Terms: Africa, sub 
Saharan: 35 results 
23/35 of these articles are 
usable primary articles for 
my study
Exclusion criteria of 16 articles 
(13) Articles focused on the 
distribution and accessibility of 
Misoprostol instead of having 
primary outcomes such as blood 
loss 
(1) Article was comparing a non-
gold standard drug (ergometrine) 
instead of oxytocin 
(1) Article was focusing on 
misoprostol as a treatment for 
retained placenta in a low resource 
setting
(1) Article was focusing on Egypt, 
Ecuador and Vietnam and not on 
the region of interest 
(7) articles were selected 
with EBL in mL as the 
primary outcome and with 
a focus on the region of 
interest
Secondary search:
Cytotec Postpartum 
hemorrhage
416 results 
Advanced search with
Mesh Terms, Africa, sub 
Saharan: 42 results 
35 of the results are the same 
articles from the primary search 
8 new results 
(all excluded)
(3) Articles have a primary 
outcome of hemoglobin 
concentration 
(3) Articles focused on 
accessibility or distribution of 
the misoprostol 
(1) Article was focusing on 
misoprostol for vaginal induction 
(1) article has primary outcomes 
measured by induction-delivery 
interval, mode of delivery, Apgar 
score, perinatal death and maternal 
complications.
7 
RESULTS 
The seven selected articles for this systematic review were categorized based on the authors’ 
names, the country of the study, the dose and route of misoprostol, the population size and 
demographic characteristics (e.g. gestational age, parity, birthweight of the newborn, etc.) 
[Table 1]. The primary outcome used for analysis is estimated blood loss (EBL). When available, 
Effect size blood loss as well as relative risk or odds ratio were used for analysis.  
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Table 1. Characteristics of articles, primary outcome (EBL) and statistical values  
Author Country 
Misoprost
ol Usage 
(dose, 
route, 
includes 
oxytocin, 
etc.) 
Population 
(sample 
size) 
Study 
Design 
(Cohort, CC, 
or RCT) 
Demographic 
characteristics 
(gestational 
age, # of 
children etc.) 
Outcomes 
(blood loss) 
 
Means (SD) 
for 
misoprostol 
and not 
misoprostol 
Effect Size 
Blood Loss 
- 
Mean 
difference 
between 
misoprostol 
vs no 
misoprostol 
/oxytocin 
 
Odds 
Ratio 
 
- 
 
Relative 
Risk 
Atukunda et 
al.   
Uganda  600 ug, 
Sublingual 
1,140, 38 – 
41 weeks 
pregnant 
women  
Double blind 
randomized 
non-
inferiority 
trial  
Misoprostol  
(n = 570)  
Mean age: 29.3 
(SD 3.4)  
Mean 
gestational age 
(weeks): 39.2 
(SD 0.8) 
Parity:  
1: 249, 43.7% 
2-4: 273, 47.9% 
5+: 47, 8.3% 
Mean 
birthweight 
(kg): 3.1 (SD 
0.4) 
 
Oxytocin  
(n= 570)  
Mean age: 29.7 
(SD 3.1) 
Mean 
gestational age 
(weeks): 39.3 
(SD 0.8) 
Parity:  
1: 219, 38.4% 
2-4: 286, 50.2% 
5+: 64 (11.3%)  
Mean 
birthweight 
(kg): 3.2 (SD 
0.5) 
At 24 h PP, 
primary PPH 
occurred in 163 
(28.6%) 
participants in 
the 
misoprostol 
group and 99 
(17.4%) 
participants in 
the 
oxytocin group 
(relative risk 
[RR] 1.64, 95% 
CI 1.32 to 2.05, 
p,0.001; 
absolute risk 
difference 
11.2%, 95% CI 
6.44 to 16.1). 
Severe PPH 
occurred in 20 
(3.6%) and 15 
(2.7%) 
participants in 
the 
misoprostol 
and oxytocin 
groups, 
respectively 
(RR 1.33, 
95% CI 0.69 to 
2.58, p = 0.391; 
absolute risk 
difference 
0.9%, 95% CI 
21.12 to 2.88) 
Mean 
measured 
blood loss was 
341.5 ml 
(standard 
deviation [SD] 
206.2) and 
304.2 ml  
(SD 190.8,  
p = 0.002) at  
2 h and 484.7 
ml (SD 213.3) 
and 432.8 ml  
(SD 203.5, 
p,0.001) at 24 
h in the 
misoprostol 
and oxytocin 
groups, 
respectively. 
RR for PPH 
(blood loss 
> or equal 
to 500ml): 
1.64 (1.32 
to 2.05) 
9 
Hofmeyr et 
al.  
South 
Africa, 
Uganda, 
Nigeria  
400 ug 
sublingual 
1103 
women: 
547 
misoprostol 
group - 546  
analyzed  
 
556 placebo 
group - 553 
analyzed  
Randomized 
placebo-
controlled, 
double-blind 
trial  
Misoprostol  
(n = 547) 
Mean age 
(year): 25  
(SD 5.6) 
Primiparous 
(n=543): 145, 
26.70 
 
Placebo  
(n = 556) 
Mean age 
(year): 28  
(SD 6.0) 
Primiparous 
(n=553): 146, 
26.40 
 
 
There was no 
significant 
difference in 
the primary 
outcome, (500 
mL or more 
within 1 hour 
of 
administration 
of the trial 
medication), 
with relative 
risk [RR], 0.64; 
95% 
confidence 
interval [CI], 
0.38–1.07), 
which occurred 
in 22/546 
(4.03%) women 
allocated to 
misoprostol 
and in 35/553 
(6.33%) women 
allocated to 
placebo.  
There was no 
significant 
difference in 
mean blood 
loss occurring 
within 1 hour 
of taking the 
tablets 
(weighted 
mean 
difference, –
9.58; 
95% CI, –22.3 
to 3.14), or in 
the incidence 
of blood loss 
of 1000 mL or 
more  
(RR, 3.70; 95% 
CI, 0.61–22.4). 
RR for PPH 
(blood loss 
> or equal 
to 500ml): 
0.64 (0.38 
to 1.07) 
Geller et al. Ghana  600 ug oral  999 doses 
distributed 
to midwives:  
646 given to 
women 
during third 
trimester 
ANC: 
529 returned 
because the 
woman 
delivered at 
an institution  
96 used at 
home  
7 used at the 
facility  
9 returned 
despite 
delivering at 
home  
 102 total 
used miso  
 
“Operation 
research 
study”  
Misoprostol  
(n = 102)  
Mean Age 
(year): 24.4  
(SD 6.56)  
Mean 
Gravidity: 3.82 
(SD 2.23) 
Mean Parity: 
2.50 (SD 2.05) 
Mean # of 
prenatal visits: 
3.70 (SD 0.57)  
 
No 
Misoprostol  
(n = 107)  
Mean Age 
(year): 26.58 
(SD 7.02)  
Mean 
Gravidity: 3.93 
(SD 2.17) 
Mean Parity: 
2.34 (SD 2.01) 
Mean # of 
prenatal visits: 
3.35 (SD 0.98)  
Misoprostol  
(n = 82)  
Blood loss: 
<350 ml: 71, 
86.6% 
350 – 499 ml: 
10, 12.2% 
+500 ml: 1, 
1.2% 
 
No 
Misoprostol  
(n = 92)  
Blood loss: 
<350 ml: 83, 
90.2% 
350 – 499 ml: 
6, 6.5% 
+500 ml: 3, 
3.3% 
-  -  
10 
Abdulkarim 
O. Musa et 
al.  
 
Nigeria  600 ug oral  Oral 
misoprostol 
(n= 100)  
 
Oxytocin 
(Intramuscular 
during Active 
Management 
of the third 
stage of labor) 
n= 100  
Double blind 
randomized 
controlled 
trial  
Misoprostol 
(n= 100)  
Mean age 
(year): 29.60 
(SD 4.71) 
Mean 
Gestational age 
(weeks): 39.38 
(SD 1.70) 
Mean Parity: 
2.22 (SD 1.10) 
Mean Birth 
weight (g): 
3004.3 (SD 
430.1)   
 
Oxytocin (n= 
100)  
Mean age 
(year): 29.50 
(SD 4.37) 
Mean 
Gestational age 
(weeks): 39.39 
(SD 1.43) 
Mean Parity: 
2.22 (SD 1.09) 
Mean Birth 
weight (g): 
3013.3 (SD 
47.3)   
Misoprostol 
(n= 100):  
Postpartum 
blood loss (ml): 
325.85 (SD 
164.72) 
PPH (+500 ml): 
15, 15%  
  
Oxytocin  
(n= 100):  
Postpartum 
blood loss (ml): 
303.95 (SD 
163.33)  
PPH (+500 ml): 
14, 14% 
 
20% of women 
given 
misoprostol 
had a 
measured 
blood loss of at 
least 500 mL, 
compared 
with 14% of 
those given 
oxytocin (RR 
1.44, 95% CI 
1.35–1.54; 
P b 0.001). 
Additionally, 
15% of women 
in the 
misoprostol 
group and 11% 
in the oxytocin 
group required 
additional 
uterotonics (RR 
1.40, 
95% CI 1.29–
1.51; P b 
0.001).  
-  Relative 
difference 
of 
postpartum 
blood loss 
(ml) (95% 
CI), 7.2  
(-9.4 to 
23.8) 
 
P value: 
0.391  
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Okonofua 
et al.   
Nigeria  800 ug 
sublingual 
Misoprostol 
used as the 
primary 
treatment 
for PPH in 3 
Nigerian 
cities (Kano, 
Jos, Lagos) 
 
Blood 
transfusions, 
Oxytocin and 
ergometrine 
if needed 
available  
 
 
Multicenter 
trial  
Kano (n = 37)  
Median age 
(year): 28  
(19 – 40)  
Parity:  
0: 2, 5.4% 
1: 5, 13.5% 
2-4: 14, 38% 
+5: 4, 10.8%  
Add. 
Treatments*:  
4, 10.8%  
 
Jos (n = 38)  
Median age 
(year): 30  
(19 – 40)  
Parity:  
0: 11, 28.9% 
1: 2, 5.3% 
2-4: 11, 28.9% 
+5: 14, 36.9%  
Add. 
Treatments*:  
2, 5.3%  
 
Lagos (n = 56)  
Median age 
(year): 30  
(18 – 36)  
Parity:  
0: 16, 28.6% 
1: 16, 28.6% 
2-4: 21, 37.5% 
+5: 3, 5.3%  
Add. 
Treatments*: 
14, 25%  
 
Add. 
Treatments*:  
IV ergometrine 
and oxytocin, 
continuous 
high-dose 
oxytocin 
infusion, blood 
transfusion and 
plasma 
expanders as 
needed.  
EBL (ml): 
Kano 
Mean: 685 
(550 – 1000) 
 
Jos 
Mean: 616 
(500 – 2500)  
 
Lagos 
Mean: 650 
(550 – 1500)  
 
 
The results 
show that 
15.3% of the 
women treated 
with 
misoprostol 
required 
additional 
treatment with 
either oxytocin, 
ergometrine or 
both, while 
32.8% of the 
women 
required blood 
transfusion. 
-  -  
12 
N. Prata et 
al. 
Tanzania  1000 ug 
rectal  
454 with 
misoprostol 
and 395 
Non-
intervention 
 Intervention 
(Misoprostol) 
group (n= 454): 
Mean age 
(year): 24.6  
(SD 4.8) 
Mean parity:  
2 (SD 1.7) 
 
Non-
Intervention 
(only referral) 
group (n= 395): 
Mean age 
(year): 26.7 (SD 
6.5) 
Mean parity: 
2.4 (SD 2.0) 
 
 
PPH (blood loss 
> +500 ml) 
Intervention: 
111/454 
(24.5%) 
 
Non-
intervention: 
73/395 (18.5%) 
 
Additional 
interventions 
among PPH 
cases: 
 
Other medical 
interventions 
for the 
referrals group 
(n=73): 
7, 9.6% 
 Odds Ratio 
for PPH: 
1.3 with 
95% CI (1.0 
– 1.7) 
 
Odds Ratio 
for 
referrals: 
0.1 with 
95% CI (0.0 
– 0.2) 
Walley et al.  Ghana 400 ug 
(powder in 
water 
orally)  
Misoprostol, 
n=203  
 
Oxytocin,  
n= 198  
Double-blind 
placebo 
controlled 
randomized 
trial  
Misoprostol 
(n=203): 
Mean maternal 
age (year)  
(n =202): 25.7 
(SD 5.0) 
Mean 
gestational age 
(weeks)  
(n= 200): 38.0 
(SD 2.0) 
Mean gravidity 
(n= 203):  
2.0 [1.0, 3.0] 
Mean Parity  
(n= 202): 1.0 
[0.0, 2.0] 
Birthweight (g) 
(n= 195): 3118 
(SD 442)  
 
Oxytocin 
(n=198): 
Mean maternal 
age (year)  
(n =196): 26.1 
(SD 5.5) 
Mean 
gestational age 
(weeks)  
(n= 196): 38.0 
(SD 1.9) 
Mean gravidity 
(n= 198):  
2.0 [1.0, 3.0] 
Mean Parity  
(n= 198): 1.0 
[0.0, 2.0] 
Birthweight (g) 
(n= 192): 3139 
(SD 518) 
Misoprostol 
(n=203) 
Estimated 
Blood Loss (ml) 
(n=202): 
190 (SD 78)  
Estimated 
Blood Loss  
> 500 (ml): 
0/202  
 
Additional 
oxytocics: 
Oxytocin: 4/168  
Ergometrine: 
2/168 
Syntrometrine: 
0/168  
 
Oxytocin 
(n=198) 
Estimated 
Blood Loss (ml) 
(n=196): 187 
(SD 78)  
Estimated 
Blood Loss  
> 500 (ml): 
2/196 
 
Additional 
oxytocics: 
Oxytocin: 5/172  
Ergometrine: 
1/172 
Syntrometrine: 
2/172 
 
 
 RR for 
estimated 
blood loss 
(EBL) in ml: 
1.8% with 
95% CI (-
7.3 to 
10.8%)  
 
P: 0.61 
13 
Innocent A. 
Ugwu et al.  
Nigeria  200 ug vs. 
400 ug 
Misoprostol  
 
alongside 
with IV 
oxytocin   
200 ug 
Misoprostol 
(n = 62)  
 
400 ug 
Misoprostol 
(n = 62)  
Randomized 
Control trial  
200 ug 
Misoprostol  
(n = 62)  
Mean age 
(year): 30.52  
(SD 5.3)  
Mean Parity:  
Primiparous: 
28 (SD 45.2)  
Multiparous: 
34 (SD 54.8)  
Mean 
gestational age 
at delivery 
(weeks): 39.0 
(SD 1.4) 
Mean 
birthweight 
(kg): 3.1 (SD 
0.5)  
 
 
400 ug 
Misoprostol  
(n = 62)  
Mean age 
(year): 30.45 
(SD 4.0)  
Mean Parity:  
Primiparous: 
27 (SD 43.5)  
Multiparous: 
35 (SD 56.5)  
Mean 
gestational age 
at delivery 
(weeks): 38.8 
(SD 1.5) 
Mean 
birthweight 
(kg): 3.1  
(SD 0.4)  
 
200 ug 
Misoprostol  
(n = 62)  
Postpartum 
blood loss, ml: 
307 (SD 145) 
Postpartum 
hemorrhage: 
Yes: 5/62 
(8.1%) 
No: 57/62 
(91.9%) 
Need for 
increase in 
oxytocin dose: 
Yes: 27/62 
(43.5%) 
No: 35/62 
(56.5%) 
Additional 
uterotonics: 
Yes: 10/62 
(16.1%) 
No: 52/62 
(83.9%) 
 
 
 
400 ug 
Misoprostol  
(n = 62)  
Postpartum 
blood loss, ml: 
296 (SD 151)  
Postpartum 
hemorrhage: 
Yes: 6/62 
(9.7%) 
No: 56/62 
(90.3%) 
Need for 
increase in 
oxytocin dose: 
Yes: 26/62 
(41.9%) 
No: 32/62 
(51.6%) 
Additional 
uterotonics: 
Yes: 9/62 
(14.5%) 
No: 53/62 
(85.5%) 
 
 
T test/Chi 
square value 
for blood loss: 
0.415 
P value: 0.679  
 
-   
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Figure 2 is a meta-analysis using a Cohen’s D (95% CI) scale. The studies conducted by Atukunda 
et al., Musa et al., Walley et al, and Ugwu et al. were specifically selected for this analysis 
because their results all included estimated mean blood loss as well as relative risk values. The 
first three articles have negative values, showing that oxytocin is favored over misoprostol 
(Figure 2). The last article by Ugwu et al. shows that this study favors the use of misoprostol 
over oxytocin. The overall result of this meta-analysis favors the use of oxytocin over 
misoprostol [-0.13 (95% CI -0.26, 0.01)]. Two main conclusions can be drawn from this meta-
analysis, (1) there is a tendency for oxytocin to have a positive effect on blood loss but (2) since 
the overall result is not statistically significant, misoprostol also have a positive effect on blood 
loss.  
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Figure 2. Meta-Analysis 1: The overall effect of misoprostol on blood loss based on collected 
data from key selected articles 
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Figure 3 is also a meta-analysis using a Cohen’s D (95% CI) scale. The effect of two different 
doses of misoprostol (400 and 600 mcg) on blood loss are compared in this meta-analysis. 
Figure 3 shows that at 600 mcg, oxytocin have a more positive and statistically significant effect 
on EBL than misoprostol even though the effect is small [-0.22 (95% CI -0.33, -0.12)]. At 400 
mcg, oxytocin has an even smaller positive effect on EBL compared to misoprostol but this 
effect is not statistically significant [-0.01 (95% CI -0.18, 0.15)].  Overall, the main conclusion 
drawn from this meta-analysis is that there is an effect modification on the overall population 
and dosage was found to be a confounder in blood loss [-0.13 (95% CI -0.26, 0.01)].  
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Figure 3.  Meta-Analysis 2: The effect of different doses of misoprostol (600 and 400 mcg) on 
EBL (mL) 
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Figure 4 is also a meta-analysis using a Cohen’s D (95% CI) scale. This meta-analysis compares 
the effect that adding oxytocin to misoprostol to control postpartum blood loss has on EBL. 
When oxytocin is added, the result shows that there is a small positive effect on blood loss 
compared to misoprostol alone [-0.13 (95% CI -0.42, 0.16)]. When oxytocin is not added to 
misoprostol, there is an even smaller positive effect on blood loss compared to misoprostol [-
0.07 (95% CI -0.22, 0.09)]. Both results from this meta-analysis are not statistically significant. 
Overall, the main conclusion drawn from this meta-analysis is that there is no statistical 
significant in adding oxytocin to a misoprostol regimen and in this case, the addition of oxytocin 
does not have a confounding effect on misoprostol [-0.13 (95% CI -0.26, 0.01)].  
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Figure 4. Meta-Analysis 3: The effect of adding oxytocin to misoprostol on EBL (mL) 
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DISCUSSION 
In Atunkunda et al article7, a double-blind randomized controlled trial was performed. This 
study was interested in comparing the administration of sublingual misoprostol (dose: 600 𝜇𝜇g) 
versus the use of intramuscular oxytocin (dose: 10 IU) to 38 – 41 weeks pregnant women in 
early active labor, at the Mbarara Regional Referral Hospital in Uganda. Results have shown 
that in settings where oxytocin is available, it should remain the preferred agent and gold 
standard for the prevention of PPH. However, sublingual misoprostol still maintains an 
important role for the prevention of severe PPH and subsequent complications in area where 
oxytocin is unavailable.  
Another interesting example is an article written by Diadhiou et al9, where they evaluated the 
benefits of misoprostol in a difference approach. The objective of this study was to 
demonstrate that PPH could be prevented among women giving birth if proper oral misoprostol 
distribution and administration was ensured by auxiliary midwives in rural Senegal. The method 
consisted of a 6-days training with auxiliary midwives, with one day dedicated to the use, 
administration and prevention of misoprostol and PPH, followed by a practicum (conducting 
deliveries during the training period). Results showed that “all study participants, whose 
deliveries were assisted by auxiliary midwives that were trained in the study, received correct 
and safe administration of misoprostol for PPH prevention”. This study also recognized in the 
discussion section that “although the study was not designed to and did not measure 
postpartum blood loss, there is substantial evidence that misoprostol effectively prevents PPH 
and severe PPH”. 
As demonstrated in the previous literatures and throughout this study, oxytocin is the gold 
standard for preventing PPH. recommended by the WHO, misoprostol has been approved to be 
the alternative drug in settings where oxytocin is not available. Multiple studies, including the 
ones selected for this review all supported these current recommendations (Figure 2). A study 
conducted by Ugwu et al. as well as results from Figure 3 demonstrated that the current dose 
of misoprostol (600 mcg) can be as low as 200 mcg and still be efficient in reducing EBL. 
Misoprostol is a prostaglandin E1 analog and its side effects have been proven to be dose 
21 
dependent16.  The idea of changing the current recommendation and eventually using a lower 
dose (200 mcg) is not only favorable for the prevention of PPH, but also for the reduction in the 
incidence of common side effects (e.g. shivering and fever). In addition, on a global health 
standpoint, since each tablet of misoprostol has a concentration of 200 mcg, a lower dose will 
be more cost effective and practical, as a single current dose (600 mcg or three tablets) will be 
able to protect three mothers instead of one.  
Despite these WHO guidelines and the evidence that misoprostol is a convenient alternative in 
settings where oxytocin is not available, implementing the use of uterotonic drugs is still a 
challenge. Perhaps this could be due to difficulty in facilitating the distribution of misoprostol or 
the proper use of the medication and studies like the one conducted by Diadhiou et al9 are 
trying to address such issues.  
Another challenge that a lot of countries in Sub-Saharan Africa might be facing is with the 
distribution of misoprostol. With very strict abortion laws, the abortive properties of 
misoprostol might be a threat in countries where abortion is restricted and viewed as a crime. 
The multi-functions of misoprostol can might be the reason why there have not been a 
significant decrease in MMR in countries of Sub-Saharan Africa despite all the global health 
efforts and WHO recommendations.  
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CONCLUSION AND FUTURE DIRECTIONS  
There have been previous individual studies evaluating the benefits of misoprostol as a reliable 
alternative to oxytocin in different countries of Sub Saharan Africa (e.g. Uganda, Nigeria, Kenya, 
Tanzania). However, a systematic approach that focuses on Sub Saharan African women of 
reproductive age has not yet been published. The World Health Organization recommends the 
use of Misoprostol in remote areas where women do not necessarily have access to a skilled 
birth attendant during childbirth.  
Based on such evidences and on the pharmaceutical benefits of Misoprostol, future directions 
of this study could include a bigger sample size with more articles, for more reliable and 
statistically significant data.  
Lastly, I believe this research project is very important because with reducing maternal death a 
2030 Millennium Developmental Goal and PPH being among the leading causes of maternal 
death worldwide, supporting the use of Misoprostol could, in a futuristic approach, improve its 
regulation, distribution and reduce maternal death. 
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